Sanofi (SNY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sanofi (SNY) Healthcare & Pipeline Overview

Sanofi is a global healthcare leader, developing and marketing pharmaceutical solutions across three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. With a strong presence in the U.S., Europe, and internationally, Sanofi leverages its research capabilities and strategic collaborations to address diverse medical needs and maintain a competitive edge.

What Is the Investment Thesis for SNY?

With a market capitalization of $103B and a P/E ratio of 22.52, the company demonstrates financial stability. A high gross margin of 71.6% and a profit margin of 17.6% indicate efficient operations. The dividend yield of 5.64% offers an attractive income stream for investors. Growth catalysts include advancements in the drug pipeline and strategic collaborations. Potential risks include regulatory challenges, competition from generic drugs, and adverse outcomes in clinical trials. Sanofi's beta of 0.32 suggests lower volatility compared to the broader market, making it a potentially stable investment.

Based on FMP financials and quantitative analysis

SNY Key Highlights

Market Cap of $103B reflects Sanofi's significant presence and value in the global healthcare market.

• P/E ratio of 22.52 indicates that the company's stock is potentially undervalued compared to its earnings.
• Gross Margin of 71.6% showcases Sanofi's efficient cost management and strong pricing power.
• Dividend Yield of 5.64% provides a substantial return for investors, highlighting Sanofi's commitment to shareholder value.
• Beta of 0.32 suggests lower volatility compared to the market, offering a degree of stability for investors.

Who Are SNY's Competitors?

SNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SNY's Key Strengths?

Diversified product portfolio across pharmaceuticals, vaccines, and consumer healthcare.

• Strong global presence and distribution network.
• Significant investment in research and development.
• High gross margin and profitability.

What Are SNY's Weaknesses?

Exposure to generic competition for established drugs.

• Dependence on regulatory approvals for new products.
• Potential for product liability claims.
• Currency exchange rate fluctuations.

What Could Drive SNY Stock Higher?

SNY catalyst: Results from Phase 3 clinical trials for key pipeline drugs in oncology and immunology are expected to be released in Q3 2026.

• Potential regulatory approvals for new vaccine candidates in the United States and Europe by the end of 2026.
• Strategic collaborations with biotechnology companies to develop innovative therapies.
• Expansion of Sanofi's presence in emerging markets, particularly in China and India.
• Integration of digital health technologies to improve patient outcomes and enhance commercial operations.

What Are the Key Risks for SNY?

Financial-distress signal — its Altman Z-Score of 1.49 sits in the distress zone (elevated bankruptcy risk).

• Intense competition from other pharmaceutical companies and generic drug manufacturers.
• Pricing pressures from government and private payers, impacting revenue and profitability.
• Adverse outcomes in clinical trials, leading to delays or failures in product development.
• Changes in healthcare regulations and policies, affecting market access and reimbursement.
• Currency exchange rate fluctuations, impacting financial results.

What Are the Growth Opportunities for SNY?

• Expansion in Emerging Markets: Sanofi has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Sanofi's pharmaceutical and vaccine products. The global emerging markets pharmaceutical market is projected to reach $500 billion by 2030, presenting a substantial opportunity for Sanofi to increase its revenue and market share. This expansion can be achieved through strategic partnerships, local manufacturing, and targeted marketing campaigns.
• Advancements in Oncology: Sanofi can capitalize on the growing oncology market by developing and commercializing innovative cancer therapies. The global oncology market is expected to reach $300 billion by 2028, driven by increasing cancer incidence and advancements in immunotherapy and targeted therapies. Sanofi's research and development efforts in oncology, coupled with strategic acquisitions and collaborations, can position the company as a key player in this high-growth area. Focus areas include novel immunotherapies and precision medicine approaches.
• Development of Novel Vaccines: Sanofi has a strong foundation in vaccine development and can further expand its portfolio by developing novel vaccines for infectious diseases. The global vaccine market is projected to reach $100 billion by 2027, driven by increasing awareness of preventive healthcare and government initiatives to promote vaccination. Sanofi's expertise in vaccine technology, combined with strategic partnerships and research collaborations, can enable the company to develop and commercialize innovative vaccines for unmet medical needs. Key areas include mRNA vaccines and combination vaccines.
• Strategic Collaborations and Acquisitions: Sanofi can drive growth through strategic collaborations and acquisitions that enhance its product portfolio and expand its market reach. Collaborations with biotechnology companies and academic institutions can provide access to innovative technologies and drug candidates. Acquisitions of complementary businesses can strengthen Sanofi's position in key therapeutic areas and expand its geographic footprint. These strategic initiatives can accelerate Sanofi's growth and enhance its long-term competitiveness.
• Digital Health Integration: Sanofi can leverage digital health technologies to improve patient outcomes and enhance its commercial operations. Digital health solutions, such as telemedicine, remote patient monitoring, and digital therapeutics, are transforming the healthcare industry. Sanofi can integrate these technologies into its product offerings and commercial strategies to improve patient engagement, enhance treatment adherence, and optimize healthcare delivery. This integration can drive revenue growth and improve Sanofi's competitive position in the evolving healthcare landscape.

What Are SNY's Competitive Advantages?

• Strong brand recognition and reputation in the healthcare industry.
• Extensive portfolio of patented pharmaceutical products and vaccines.
• Global distribution network and market presence.
• Significant investment in research and development, leading to innovative therapies.
• Strategic collaborations and partnerships with leading healthcare organizations.

What Does SNY Do?

Founded in 1973 and headquartered in Paris, France, Sanofi has evolved into a global healthcare giant with a diverse portfolio of therapeutic solutions. Originally known as Sanofi-Aventis, the company rebranded in 2011 to reflect its strategic vision. Sanofi operates through three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment focuses on specialty care products, including human monoclonal antibodies, treatments for multiple sclerosis, neurology, immunology, rare diseases, oncology, and diabetes. The Vaccines segment provides a range of pediatric and adult vaccines, including those for poliomyelitis, influenza, and meningitis. The Consumer Healthcare segment offers over-the-counter products for allergy, cough and cold, pain relief, and digestive health. Sanofi's global presence extends across the United States, Europe, and other international markets, supported by a workforce of over 82,000 employees. The company actively engages in research and development, with numerous pharmaceutical products and vaccines in the pipeline. Strategic collaborations, such as those with GlaxoSmithKline and Stanford University School of Medicine, enhance Sanofi's innovation and market reach. Sanofi's commitment to addressing unmet medical needs positions it as a key player in the healthcare industry.

What Products and Services Does SNY Offer?

• Researches and develops therapeutic solutions for various diseases.
• Manufactures pharmaceutical products, including specialty care medicines.
• Markets and distributes its products globally.
• Produces and supplies a wide range of vaccines for pediatric and adult use.
• Offers consumer healthcare products for allergy, cough, cold, and pain relief.
• Engages in strategic collaborations to enhance its research and development capabilities.
• Provides medicines for diabetes and cardiovascular conditions.

How Does SNY Make Money?

• Develops and commercializes pharmaceutical products and vaccines.
• Generates revenue through the sale of prescription drugs, vaccines, and consumer healthcare products.
• Invests heavily in research and development to discover and develop new therapies.
• Forms strategic alliances and partnerships to expand its product portfolio and market reach.

What Industry Does SNY Operate In?

Sanofi operates in the highly competitive global pharmaceutical industry, characterized by intense research and development, stringent regulatory oversight, and patent protection. The market is driven by an aging global population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Sanofi competes with major players like Pfizer Inc. (PFE), Amgen Inc. (AMGN), and Bristol-Myers Squibb Company (BMY). The industry is experiencing growth in biologics, personalized medicine, and digital health solutions. Sanofi's diversified portfolio and strategic collaborations position it to capitalize on these trends.

Who Are SNY's Key Customers?

• Patients who require prescription medications and vaccines.
• Healthcare providers who prescribe and administer Sanofi's products.
• Pharmacies and retailers that sell Sanofi's consumer healthcare products.
• Government agencies and public health organizations that purchase vaccines.
• Hospitals and clinics that use Sanofi's pharmaceutical products.

Sanofi has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 4.9% above estimates on average.

Sanofi's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.49 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Sanofi stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. SNY trades at a trailing price-to-earnings ratio of 22.52, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 18.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.99 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.

Sanofi (SNY) Valuation Context

Valued at $103B, SNY is classified as a large-cap stock. Analyst price targets span from $49.00 to $50.00, with a consensus of $49.50. At the current price of $42.74, that implies approximately 16% upside potential. Relative to its peer group, SNY's quantitative score of 83/100 is roughly in line with the peer average of 74/100.

SNY Revenue & Earnings Trend

In Q2 FY2026, SNY generated $12.30B in top-line revenue, marking a sequential increase of 9.4%. The company recorded net income of $343.0M, with diluted EPS of $0.14. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SNY averaged $0.41 in diluted EPS.

Company Profile

Sanofi operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Belén Garijo López. SNY has traded publicly since 2002.

SNY Financials

SNY Latest News

SNY Analyst Consensus

SNY MoonshotScore

Latest Sanofi Analysis

SNY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources